A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation

Trial Profile

A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Vernakalant (Primary) ; Amiodarone
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 04 Aug 2017 Status changed from completed to discontinued.
    • 20 Feb 2013 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 17 Oct 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top